The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)
Open accessAbstract
Purpose: Concerns regarding neurocognitive toxicity of whole-brain radiotherapy (WBRT) have motivated development of alternative, dose-intensive chemotherapeutic strategies as consolidation in primary CNS lymphoma (PCNSL). We performed a multicenter study of high-dose consolidation, without WBRT, in PCNSL. Objectives were to determine: one, rate of complete response (CR) after remission induction therapy with methotrexate, temozolomide, and rituximab (MT-R); two, feasibility of a two-step approach using high-dose consolidation with etoposide plus cytarabine (EA); three, progression-free survival (PFS); and four, correlation between clinical and molecular prognostic factors and outcome. Patients and Methods: Forty-four patients with newly diagnosed PCNSL were treated with induction MT-R, and patients who achieved CR received EA consolidation. We performed a prospective analysis of molecular prognostic biomarkers in PCNSL in the setting of a clinical trial. Results: The rate of CR to MT-R was 66%. The overall 2-year PFS was 0.57, with median follow-up of 4.9 years. The 2-year time to progression was 0.59, and for patients who completed consolidation, it was 0.77. Patients age > 60 years did as well as younger patients, and the most significant clinical prognostic variable was treatment delay. High BCL6 expression correlated with shorter survival. Conclusion: CALGB 50202 demonstrates for the first time to our knowledge that dose-intensive consolidation for PCNSL is feasible in the multicenter setting and yields rates of PFS and OS at least comparable to those of regimens involving WBRT. On the basis of these encouraging results, an intergroup study has been activated comparing EA consolidation with myeloablative chemotherapy in this randomized trial in PCNSL, in which neither arm involves WBRT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationAbrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 914
DeAngelis, L. M., Seiferheld, W., Schold, S. C., Fisher, B., & Schultz, C. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.013 · Cited by 738
Ferreri, A. J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G. A., Frezzato, M., Cabras, M. G., Fabbri, A., Corazzelli, G., Ilariucci, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61416-1 · Cited by 662
Long-term survival in primary CNS lymphoma.
Abrey, L. E., DeAngelis, L. M., & Yahalom, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.859 · Cited by 577
Batchelor, T., Carson, K., O’Neill, A., Grossman, S. A., Alavi, J., New, P., Hochberg, F., & Priet, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.036 · Cited by 546
Camilleri-Broët, S., Crinière, E., Broët, P., Delwail, V., Mokhtari, K., Moreau, A., Kujas, M., Raphaël, M., Iraqi, W., Sautès-Fridman, C., et al. (2006) · Blood · doi:10.1182/blood-2005-03-1024 · Cited by 371
Sun, A., Bae, K., Gore, E. M., Movsas, B., Wong, S. J., Meyers, C. A., Bonner, J. A., Schild, S. E., Gaspar, L. E., Bogart, J. A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6053 · Cited by 369
Batchelor, T., & Loeffler, J. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8819 · Cited by 362
Soussain, C., Suzan, F., Hoang-Xuan, K., Cassoux, N., Levy, V., Azar, N., Belanger, C., Achour, E., Ribrag, V., Gerber, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.742 · Cited by 322
A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Cerchietti, L. C., Ghetu, A. F., Zhu, X., Da Silva, G. F., Zhong, S., Matthews, M., Bunting, K. L., Polo, J. M., Farès, C., Arrowsmith, C. H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.050 · Cited by 288
Winter, J. N. (2006) · Blood · doi:10.1182/blood-2005-10-4222 · Cited by 265
Angelov, L., Doolittle, N. D., Kraemer, D. F., Siegal, T., Barnett, G. H., Peereboom, D. M., Stevens, G., McGregor, J., Jahnke, K., Lacy, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3789 · Cited by 236
Osoba, D., Brada, M., Yung, W. K. A., & Prados, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1481 · Cited by 213
Gene expression and angiotropism in primary CNS lymphoma
Rubenstein, J. L., Fridlyand, J., Shen, A., Aldape, K., Ginzinger, D., Batchelor, T., Treseler, P., Berger, M., McDermott, M., Prados, M., et al. (2006) · Blood · doi:10.1182/blood-2005-03-0897 · Cited by 210
Self-citationBraaten, K. M., Betensky, R. A., de Leval, L., Okada, Y., Hochberg, F. H., Louis, D. N., Harris, N. L., & Batchelor, T. T. (2003) · PubMed · Cited by 193
Montesinos-Rongen, M., Küppers, R., Schlüter, D., Spieker, T., Van Roost, D., Schaller, C., Reifenberger, G., Wiestler, O. D., & Deckert-Schlüter, M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65526-5 · Cited by 184
Herrlinger, U., Schabet, M., Brugger, W., Kortmann, R., Küker, W., Deckert, M., Engel, C., Schmeck‐Lindenau, H., Mergenthaler, H., Krauseneck, P., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10102 · Cited by 180
Thompsett, A. R., Ellison, D. W., Stevenson, F. K., & Zhu, D. (1999) · Blood · doi:10.1182/blood.v94.5.1738 · Cited by 167
Temozolomide as salvage treatment in primary brain lymphomas
Reni, M., Zaja, F., Mason, W., Perry, J., Mazza, E., Spina, M., Bordonaro, R., Ilariucci, F., Faedi, M., Corazzelli, G., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603660 · Cited by 163
Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas
Kluk, M. J., Chapuy, B., Sinha, P., Roy, A., Cin, P. D., Neuberg, D. S., Monti, S., Pinkus, G. S., Shipp, M. A., & Rodig, S. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033813 · Cited by 162
Wieduwilt, M. J., Valles, F. E., Issa, S., Behler, C. M., Hwang, J. Q., McDermott, M., TRESELER, P. A., O’Brien, J. M., Shuman, M. A., Cha, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0625 · Cited by 128
Self-citationOsoba, D., Brada, M., Yung, W. K. A., & Prados, M. D. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00165-9 · Cited by 97
Rösen‐Wolff, A., Soldan, W., Heyne, K., Bickhardt, J., Gahr, M. L., & Roesler, J. (2001) · Annals of Hematology · doi:10.1007/s002770000230 · Cited by 90
Cited by
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Hoang-Xuan, K., Bessell, E., Bromberg, J., Hottinger, A. F., Preusser, M., Rudà, R., Schlegel, U., Siegal, T., Soussain, C., Abacioglu, U., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00076-5 · Cited by 411
Metadata
- Authors
- Rubenstein, J. L., Hsi, E. D., Johnson, J. L., Jung, S.-H., Nakashima, M. O., Grant, B., Cheson, B. D., & Kaplan, L. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-09-01
- Volume
- 31
- Issue
- 25
- Pages
- 3061-3068
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2115623838
- Cited by
- 509
- References
- 24
- FWCI
- 24.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.